Medscape19d
Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition
We sought to describe their association with euglycemic diabetic ketoacidosis (euDKA ... or malaise or develop a metabolic acidosis in the setting of SGLT-2 inhibitor therapy should be promptly ...
Healio26d
DKA concerns remain paramount in FDA’s denial of sotagliflozin for type 1 diabetes
In March 2019, the FDA opted not to approve sotagliflozin when it issued a complete response letter. Concerns over DKA were again brought up again when the FDA Endocrinologic and Metabolic Drugs ...